US20060251725A1 - Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof - Google Patents
Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof Download PDFInfo
- Publication number
- US20060251725A1 US20060251725A1 US10/565,834 US56583406A US2006251725A1 US 20060251725 A1 US20060251725 A1 US 20060251725A1 US 56583406 A US56583406 A US 56583406A US 2006251725 A1 US2006251725 A1 US 2006251725A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- unsubstituted
- organic solvent
- nanoparticles
- cucurbituril
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- XHQKETSTMFWHRD-HDICACEKSA-N C=C1N2CCCCCN1[C@]1(C)N3CCCCCN(C3=C)[C@]21C Chemical compound C=C1N2CCCCCN1[C@]1(C)N3CCCCCN(C3=C)[C@]21C XHQKETSTMFWHRD-HDICACEKSA-N 0.000 description 5
- XZHOADXVCAOEAX-ADGLTFJYSA-N CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.C[C@]12N3CCCCCN(C3=O)[C@@]1(C)N1CCCCCN2C1=O Chemical compound CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.C[C@]12N3CCCCCN(C3=O)[C@@]1(C)N1CCCCCN2C1=O XZHOADXVCAOEAX-ADGLTFJYSA-N 0.000 description 1
- RNUMZCRALZZCGI-UHFFFAOYSA-N CCN1C(=O)NC2NC(=O)N(CC)C21 Chemical compound CCN1C(=O)NC2NC(=O)N(CC)C21 RNUMZCRALZZCGI-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the present invention relates to nanoparticles including a cucurbituril derivative. More particularly, the present invention relates to nanoparticles prepared by the aggregation of cucurbituril derivatives, a pharmaceutical composition including the nanoparticles, and preparation methods thereof.
- a drug delivery system requires a drug carrier and formulation. Synthesis of various polymers used as such a drug carrier has been predominantly studied. A representative of these synthetic polymers is a biodegradable polymer.
- a biodegradable polymer which is non-toxic in vivo such as polylactide (PLA), poly(lactide-co-glycolide) (PLGA), polyethyleneglycol (PEG), and poly(alkylcyanoacrylate), has been actively studied for a drug delivery system.
- Cucurbituril was first reported by R. Behrend, E. Meyer, F. Rusche in 1905 ( Liebigs Ann. Chem. 1905, 339, 1). According to their report, the condensation of glycoluril and excess formaldehyde in the presence of hydrochloric acid (HCl) produces an amorphous solid. Dissolution of the amorphous solid in hot concentrated sulfuric acid and then dilution of the resultant solution with water produce a crystalline substance. However, they wrongly characterized this substance as C 10 H 11 N 7 O 4 .2H 2 O without revealing the structure of this substance.
- HCl hydrochloric acid
- WO 00/68232 discloses cucurbit[n]uril represented by Reference Diagram 1 below:
- n is an integer of 4 to 12.
- cucurbituril derivatives are compounds including unsubstituted glycoluril monomer units.
- Cucurbituril is a macrocyclic compound and has a lipophilic cavity and two hydrophilic entrances at upper and lower portions.
- lipophilic interactions occur in the cavity of cucurbituril, and hydrogen bonds, polar-polar interactions, and positive charge-polar interactions occur in the two entrances having six carbonyl groups. Therefore, cucurbituril has retention capacity for various compounds by very stable non-covalent bond with these compounds (see Table 1).
- cucurbituril forms a complex, particularly, with a compound having an amino group or a carboxyl group by very stable non-covalent linkage. Based on such characteristics, studies about application of cucurbituril in various areas have been continuously conducted.
- the present inventors reported a complex formation between oxaliplatin approved as an anticancer agent by the Food Drug Administration (FDA) and cucurbituril used as a drug delivery system by a stable non-covalent bond (PCT/KR02/01755). Furthermore, the present inventors reported an enhancement of DNA binding capacity by cucurbituril-containing pseudo-rotaxane and a use of a cucurbituril-based dendrimer as a gene delivery system [KR01-7169, Angew. Chem. Int. Ed., 2000 and 2001].
- a self-assembled monolayer made of cucurbituril which is formed on a gold surface, has a reproducible and stable non-covalent binding capacity with proteins such as lysozyme and glucose oxidase (GOD).
- proteins such as lysozyme and glucose oxidase (GOD).
- cucurbituril cannot be used as a drug delivery system only for a single molecule drug having an amine group, an ammonium group, or a carboxyl group, but also for a protein or polypeptide drug.
- cucurbituril has a low solubility and no active functional groups that can be easily substituted by various substituents, and thus, its utility is extremely limited.
- cucurbituril is subsidiary to cyclodextrin which is an existing promising drug delivery system.
- extensive studies about a use of cucurbituril as a drug delivery system have not been conducted.
- the present invention was completed based on the above-described non-covalent binding properties of cucurbiturils and easy introduction of various substituents into cucurbituril derivatives.
- the present invention provides nanoparticles including a cucurbituril derivative.
- the present invention also provides a pharmaceutical composition in which a drug is loaded into the nanoparticles.
- the present invention also provides a method of preparing the nanoparticles.
- the present invention also provides a method of preparing the pharmaceutical composition.
- nanoparticles prepared by the aggregation of cucurbituril derivatives of Formula 1 below and having a particle size of 1 to 1,000 nm:
- X is O, S, or NH
- a 1 and A 2 are respectively OR 1 and OR 2 , SR 1 and SR 2 , or NHR 1 and NHR 2 ;
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted alkyl of C 1 -C 30 , a substituted or unsubstituted alkenyl of C 2 -C 30 , a substituted or unsubstituted alkynyl of C 2 -C 30 , a substituted or unsubstituted carbonylalkyl of C 2 -C 30 , a substituted or unsubstituted thioalkyl of C 1 -C 30 , a substituted or unsubstituted alkylthiol of C 1 -C 30 , a substituted or unsubstituted alkoxy of C 1 -C 30 , a substituted or unsubstituted hydroxyalkyl of C 1 -C 30 , a substituted or unsubstituted alkylsilyl of C 1 -C 30 , a substituted or unsubstituted aminoal
- n is an integer of 4 to 20.
- a pharmaceutical composition in which a pharmaceutically active substance is loaded as a guest molecule into nanoparticles formed by the aggregation of cucurbituril derivatives of formula 1 above.
- a method of preparing nanoparticles by the agglomeration of cucurbituril derivatives which includes: dissolving cucurbituril derivatives of Formula 1 in an organic solvent to obtain a reaction solution; adding water to the reaction solution followed by dispersing; distilling the dispersed solution in a temperature range from a boiling point of the organic solvent to 100° C. to remove the organic solvent; and cooling the resultant solution to room temperature.
- a method of preparing a pharmaceutical composition in which a pharmaceutically active substance as a guest molecule is loaded into the above-prepared nanoparticles which includes: dissolving a cucurbituril derivative of Formula 1 and the pharmaceutically active substance in an organic solvent to obtain a reaction solution; adding water to the reaction solution followed by dispersing; distilling the dispersed solution in a temperature range from a boiling point of the organic solvent to 100° C. to remove the organic solvent; and cooling the resultant solution to room temperature.
- FIG. 1 is a scanning electron microscopic image of nanoparticles prepared using octanesulfanylpropyloxycucurbit[12]uril according to a method of the present invention.
- the present invention provides nanoparticles prepared by the aggregation of cucurbituril derivatives of formula 1 below and having cavities and a particle size of 1 to 1,000 nm:
- X is O, S, or NH
- a 1 and A 2 are respectively OR 1 and OR 2 , SR 1 and SR 2 , or NHR 1 and NHR 2 ;
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted alkyl of C 1 -C 30 , a substituted or unsubstituted alkenyl of C 2 -C 30 , a substituted or unsubstituted alkynyl of C 2 -C 30 , a substituted or unsubstituted carbonylalkyl of C 2 -C 30 , a substituted or unsubstituted thioalkyl of C 1 -C 30 , a substituted or unsubstituted alkylthiol of C 1 -C 30 , a substituted or unsubstituted alkoxy of C 1 -C 30 , a substituted or unsubstituted hydroxyalkyl of C 1 -C 30 , a substituted or unsubstituted alkylsilyl of C 1 -C 30 , a substituted or unsubstituted aminoal
- n is an integer of 4 to 20.
- the nanoparticles may be formed by the aggregation of a biodegradable polymer in addition to the cucurbituril derivatives.
- the additional use of the biodegradable polymer reduces the content of the cucurbituril derivative without an adverse effect and minimizes a potential side effect in the human body.
- the biodegradable polymer include, but are not limited to, poly(lactide-co-glycolide) (PLGA), polyethyleneglycol (PEG), poly(alkylcyanoacrylate), poly- ⁇ -caprolactone, cellulose derivative, albumin, gelatin, alginate, and a mixture thereof.
- the nanoparticles resulting from the aggregation of the cucurbituril derivatives of formula 1 can be used as a drug carrier.
- the pharmaceutically active substance is loaded as a guest molecule into the cavities of the nanoparticles.
- the pharmaceutically active substance may be an organic compound, a protein, or a gene.
- organic compound examples include, but are not limited to, hydrocortisone, prednisolone, spironolactone, testosterone, megesterol acetate, danasole, progesterone, indomethacin, amphotericin B, and a mixture thereof.
- the protein examples include, but are not limited to, human growth hormone, G-CSF (granulocyte colony-stimulating factor), GM-CSF (granulocyte-macrophage colony-stimulating factor), erythropoietin, vaccine, antibody, insulin, glucagon, calcitonin, ACTH (adrenocorticotropic hormone), somatostatin, somatotropin, somatomedin, parathyroid hormone, thyroid hormone, hypothalamus secretion, prolactin, endorphin, VEGF (vascular endothelial growth factor), enkephalin, vasopressin, nerve growth factor, non-naturally occurring opioid, interferon, asparaginase, alginase, superoxide dismutase, trypsin, chymotrypsin, pepsin, and a mixture thereof.
- G-CSF granulocyte colony-stimulating factor
- GM-CSF granulocyte-macrophag
- a method of preparing the nanoparticles include: dissolving the cucurbituril derivative of Formula 1 in an organic solvent to obtain a reaction solution; adding water to the reaction solution followed by dispersing; distilling the dispersed solution in a temperature range from a boiling point of the organic solvent to 100° C. to remove the organic solvent; and cooling the resultant solution to room temperature.
- a method of preparing the pharmaceutical composition in which the pharmaceutically active substance as a guest molecule is loaded into the nanoparticles includes: dissolving the cucurbituril derivative of Formula 1 and the pharmaceutically active substance in an organic solvent to obtain a reaction solution; adding water to the reaction solution followed by dispersing; distilling the dispersed solution in a temperature range from a boiling point of the organic solvent to 100° C. to remove the organic solvent; and cooling the resultant solution to room temperature.
- a biodegradable polymer may be dissolved in the organic solvent, together with the cucurbituril derivative, to obtain the reaction solution.
- the biodegradable polymer may be PLGA, PEG, poly(alkylcyanoacrylate), poly- ⁇ -caprolactone, cellulose derivative, albumin, gelatin, alginate, or a mixture thereof, but is not limited thereto.
- the organic solvent is a solvent capable of solubilizing the cucurbituril derivative and may be chloroform, dimethylsulfoxide, dichloromethane, dimethylformamide, tetrahydrofuran, or a mixture thereof, but is not limited thereto.
- water is used in a higher amount than the reaction solution.
- water is used in an amount of more than about 10-fold of the volume of the reaction solution.
- the reaction solution must be uniformly dispersed in water.
- the dispersing is carried out by sonication with a sonicator.
- the organic solvent is removed by distillation with heating above the boiling point of the organic solvent.
- the reaction temperature is reduced to room temperature after the removal of the organic solvent, an emulsion is created.
- Optical microscope, scanning electron microscope, or transmission electron microscope analysis reveals nanoparticles with a particle size of 1 to 1,000 nm.
- the SEM image is shown in FIG. 1 .
- the present invention provides nanoparticles formed by the aggregation of cucurbituril derivatives, a pharmaceutical composition in which a drug is loaded into the nanoparticles, and preparation methods thereof.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/175,980 US7829698B2 (en) | 2003-07-26 | 2008-07-18 | Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030051841A KR100554156B1 (ko) | 2003-07-26 | 2003-07-26 | 쿠커비투릴 유도체가 응집되어 형성된 나노 입자, 그 나노입자에 약물이 담지된 약제학적 조성물, 및 이들의 제조방법 |
KR10-2003-0051841 | 2003-07-26 | ||
PCT/KR2004/001874 WO2005010004A1 (en) | 2003-07-26 | 2004-07-26 | Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/175,980 Division US7829698B2 (en) | 2003-07-26 | 2008-07-18 | Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060251725A1 true US20060251725A1 (en) | 2006-11-09 |
Family
ID=36123640
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/565,834 Abandoned US20060251725A1 (en) | 2003-07-26 | 2004-07-26 | Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof |
US12/175,980 Expired - Fee Related US7829698B2 (en) | 2003-07-26 | 2008-07-18 | Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/175,980 Expired - Fee Related US7829698B2 (en) | 2003-07-26 | 2008-07-18 | Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof |
Country Status (5)
Country | Link |
---|---|
US (2) | US20060251725A1 (ko) |
EP (1) | EP1651651A4 (ko) |
JP (1) | JP4574615B2 (ko) |
KR (1) | KR100554156B1 (ko) |
WO (1) | WO2005010004A1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105561330A (zh) * | 2016-01-25 | 2016-05-11 | 四川大学 | 一种人降钙素-葫芦脲复合制剂及其制备方法 |
CN112341641A (zh) * | 2020-11-23 | 2021-02-09 | 南京工业大学 | 一种双网络颗粒凝胶及其制备方法 |
US20210130613A1 (en) * | 2019-10-30 | 2021-05-06 | Korea Institute Of Science And Technology | Positively charged nanoparticles, use thereof, and preparation method thereof |
CN113968906A (zh) * | 2021-11-22 | 2022-01-25 | 四川大学 | 一种利用外壁季铵化葫芦脲赋予胶原持久抗菌功能的方法 |
US11576846B2 (en) * | 2018-03-22 | 2023-02-14 | Aqdot Limited | Emulsion stabiliser |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0957389A1 (en) | 1998-05-13 | 1999-11-17 | Eastman Kodak Company | Precision assembly technique |
KR20060119979A (ko) | 2003-09-12 | 2006-11-24 | 뉴사우쓰 이노베이션스 피티와이 리미티드 | 쿠쿠르비트우릴의 제조 방법 |
KR20050102295A (ko) * | 2004-04-21 | 2005-10-26 | 학교법인 포항공과대학교 | 리포좀 및 그 제조방법 |
KR100638516B1 (ko) * | 2005-04-21 | 2006-11-06 | 학교법인 포항공과대학교 | 고분자 캡슐 및 그 제조방법 |
KR101118587B1 (ko) * | 2009-08-17 | 2012-06-12 | 포항공과대학교 산학협력단 | 감응성 고분자 캡슐 및 그 제조방법 |
KR101201473B1 (ko) | 2009-12-29 | 2012-11-15 | 포항공과대학교 산학협력단 | 자기 조립형 약물 및 세포 전달체의 제조 방법 및 이에 의해 제조된 자기 조립형 약물 및 세포 전달체 |
US10988618B2 (en) | 2011-09-23 | 2021-04-27 | Dystar Hilton Davis Corp. | Self-assembled nano-structured particle and methods for preparing |
PL2758037T3 (pl) | 2011-09-23 | 2018-10-31 | Emerald Hilton Davis, Llc | Samoistnie złożona cząsteczka nanostrukturalna i sposób otrzymywania |
US9101669B2 (en) | 2012-01-31 | 2015-08-11 | Postech Academy-Industry Foundation | Self-assembed conjugate and use thereof |
KR101404973B1 (ko) | 2012-11-16 | 2014-06-10 | 포항공과대학교 산학협력단 | 쿠커비투릴을 이용한 인슐린 나노 섬유화 제어 방법 |
WO2017062622A1 (en) * | 2015-10-06 | 2017-04-13 | Massachusetts Institute Of Technology | Supramolecular modification of proteins |
KR101997474B1 (ko) * | 2016-06-13 | 2019-07-09 | 기초과학연구원 | 쿠커비투[n]릴을 이용하여 신경전달물질을 제어하는 방법 및 이의 용도 |
GB2556619B (en) * | 2016-08-24 | 2019-01-02 | Aqdot Ltd | Suspension compositions |
CN111821472B (zh) * | 2019-04-17 | 2021-11-19 | 中国科学院武汉物理与数学研究所 | 一种可以递送疏水性药物的超极化129Xe磁共振分子探针 |
JPWO2021172197A1 (ko) * | 2020-02-26 | 2021-09-02 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030008818A1 (en) * | 2000-12-19 | 2003-01-09 | California Institute Of Technology And Insert Therapeutics, Inc | Compositions containing inclusion complexes |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19603377B4 (de) | 1996-01-31 | 2006-12-14 | Sensient Imaging Technologies Gmbh | Verfahren zur Herstellung von Cucurbituril |
AUPQ023299A0 (en) * | 1999-05-07 | 1999-06-03 | Unisearch Limited | Cucurbiturils and method for synthesis |
EP1094065B1 (en) * | 1999-10-21 | 2003-12-17 | Pohang University of Science and Technology Foundation | Preparation methods of cucurbituril derivatives |
BR0102252B1 (pt) * | 2001-04-10 | 2013-10-22 | Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso | |
DE10126394A1 (de) * | 2001-05-28 | 2002-12-05 | Syntec Ges Fuer Chemie Und Tec | Neue Komposite auf der Grundlage von in anorganischen Matrizen eingelagertem Cucurbiturilen sowie deren Herstellung und Anwendung |
KR100400085B1 (ko) * | 2001-07-04 | 2003-09-29 | 학교법인 포항공과대학교 | 수용성 및 지용성 쿠커비투릴 유도체, 그 제조방법, 그분리방법 및 용도 |
KR100484504B1 (ko) * | 2001-09-18 | 2005-04-20 | 학교법인 포항공과대학교 | 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물 |
KR100499275B1 (ko) * | 2002-01-03 | 2005-07-01 | 학교법인 포항공과대학교 | 하이드록시쿠커비투릴 및 그 유도체, 그 제조방법 및이들의 용도 |
KR100528959B1 (ko) | 2003-02-11 | 2005-11-16 | 학교법인 포항공과대학교 | 쿠커비투릴이 결합된 실리카 겔 |
US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
-
2003
- 2003-07-26 KR KR1020030051841A patent/KR100554156B1/ko not_active IP Right Cessation
-
2004
- 2004-07-26 EP EP04774205A patent/EP1651651A4/en not_active Ceased
- 2004-07-26 US US10/565,834 patent/US20060251725A1/en not_active Abandoned
- 2004-07-26 JP JP2006521785A patent/JP4574615B2/ja not_active Expired - Fee Related
- 2004-07-26 WO PCT/KR2004/001874 patent/WO2005010004A1/en active Application Filing
-
2008
- 2008-07-18 US US12/175,980 patent/US7829698B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030008818A1 (en) * | 2000-12-19 | 2003-01-09 | California Institute Of Technology And Insert Therapeutics, Inc | Compositions containing inclusion complexes |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105561330A (zh) * | 2016-01-25 | 2016-05-11 | 四川大学 | 一种人降钙素-葫芦脲复合制剂及其制备方法 |
US11576846B2 (en) * | 2018-03-22 | 2023-02-14 | Aqdot Limited | Emulsion stabiliser |
US20210130613A1 (en) * | 2019-10-30 | 2021-05-06 | Korea Institute Of Science And Technology | Positively charged nanoparticles, use thereof, and preparation method thereof |
CN112341641A (zh) * | 2020-11-23 | 2021-02-09 | 南京工业大学 | 一种双网络颗粒凝胶及其制备方法 |
CN113968906A (zh) * | 2021-11-22 | 2022-01-25 | 四川大学 | 一种利用外壁季铵化葫芦脲赋予胶原持久抗菌功能的方法 |
Also Published As
Publication number | Publication date |
---|---|
KR100554156B1 (ko) | 2006-02-22 |
JP2007500185A (ja) | 2007-01-11 |
JP4574615B2 (ja) | 2010-11-04 |
KR20050013019A (ko) | 2005-02-02 |
US7829698B2 (en) | 2010-11-09 |
US20080279950A1 (en) | 2008-11-13 |
EP1651651A4 (en) | 2008-09-17 |
WO2005010004A1 (en) | 2005-02-03 |
EP1651651A1 (en) | 2006-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7829698B2 (en) | Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof | |
US20070212404A1 (en) | Liposome And Method Of Preparing The Same | |
EP1871823B1 (en) | Polymer capsule and process for the preparation thereof | |
EP2007432B1 (en) | Biodegradable cationic polymers | |
US20120148670A1 (en) | Sensitive polymer capsule and method of manufacturing the same | |
US9757342B2 (en) | Method for preparing protein cage, and in situ method for preparing hydrophobic additive-supported core-shell structured polymer-protein particles | |
CN112999352A (zh) | 一种rgd/ptx@zif-90药物传递系统及其制备方法 | |
Wang et al. | Facial solid-phase synthesis of well-defined zwitterionic amphiphiles for enhanced anticancer drug delivery | |
CN101357990B (zh) | 分子量可控且生物相容性好的蝌蚪形聚合物及其制备方法 | |
Cheng et al. | A perylenediimide-based nanocarrier monitors curcumin release with an “off–on” fluorescence switch | |
Wu et al. | Multifunctional polypeptide–PEO nanoreactors via the hydrophobic switch | |
KR101512759B1 (ko) | 이온성 작용기가 곁사슬 또는 말단에 도입된 온도감응성 폴리에틸렌글리콜/폴리에스터 블록 공중합체 및 이의 제조방법 | |
KR101118588B1 (ko) | 감응성 고분자 캡슐 및 그 제조방법 | |
KR100670948B1 (ko) | 쿠커비투릴 유도체 단일 분자에 공유결합된 탄수화물다량체 | |
US20240156982A1 (en) | Method of forming peptide-coated nanoparticles | |
KR102554844B1 (ko) | Tpgs-솔루플러스 결합체 및 이를 포함하는 온도감응성 주입형 하이드로겔 | |
CN114874422B (zh) | 一种聚烷基胺、其合成方法、颗粒及用途 | |
CN114209848B (zh) | 一种具有运输siRNA功能的铂肽共聚物的制备方法及其应用 | |
CN115536730B (zh) | 一种穿越血脑屏障的多肽及其制备方法、纳米结构及其制备方法和应用 | |
CN115557851B (zh) | 一种氨基脂质、其合成方法、颗粒及用途 | |
CN115232195A (zh) | 寡肽二维纳米材料及其应用 | |
CN114652846A (zh) | 酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药及制备方法和应用 | |
CN115109258A (zh) | 7-乙基-10-羟基喜树碱聚合物、制备方法及其应用 | |
CN118146143A (zh) | 喹啉类脂质衍生物及其用途 | |
CN115120739A (zh) | 一种rgd肽修饰的肿瘤靶向聚合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: POSTECH FOUNDATION, KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, KIMOON;JON, SANG YONG;JEON, YOUNG JIN;AND OTHERS;REEL/FRAME:017510/0597 Effective date: 20051231 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |